Adenosine

Generic Name
Adenosine
Brand Names
Adenocard, Viva-drops Lubricating Eye Drops
Drug Type
Small Molecule
Chemical Formula
C10H13N5O4
CAS Number
58-61-7
Unique Ingredient Identifier
K72T3FS567
Background

The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by dipyridamole and [regadenson]. Adenosine is also indic...

Indication

Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy in patients unable to adequately exercise. It is also indicated to convert sinus rhythm of paroxysmal supraventricular tachycardia.

Associated Conditions
Paroxysmal Supraventricular Tachycardia (PSVT), Pulmonary Arterial Hypertension (PAH), SVT, Supraventricular Tachycardia (SVT)
Associated Therapies
-
Clinical Trials
Related News

Blood Markers for Inflammation and Coronary Artery Vasoreactivity Testing in Patients With Chest Pain and Normal Coronary Arteries

First Posted Date
2010-07-15
Last Posted Date
2011-02-23
Lead Sponsor
St George's Healthcare NHS Trust
Target Recruit Count
50
Registration Number
NCT01162824
Locations
🇬🇧

Department of Cardiology, St George's Healthcare NHS Trust, London, England, United Kingdom

Comparison of Intravenous Adenosine Infusion With Regadenoson Bolus for Inducing Maximal Coronary Hyperemia

Phase 1
Completed
Conditions
Coronary Artery Disease
Interventions
Drug: adenosine
Drug: regadenoson
First Posted Date
2010-07-13
Last Posted Date
2017-06-23
Lead Sponsor
St. Louis University
Target Recruit Count
46
Registration Number
NCT01161121
Locations
🇺🇸

University of Florida, Jacksonville, Florida, United States

🇺🇸

St. Louis University, Saint Louis, Missouri, United States

Intracoronary Adenosine Administration to Prevent Periprocedural Myonecrosis in Elective Coronary Angioplasty

Phase 3
Completed
Conditions
Coronary Angioplasty
Interventions
Drug: Placebo
Drug: Adenosine
First Posted Date
2010-06-22
Last Posted Date
2011-11-08
Lead Sponsor
Azienda Ospedaliero Universitaria Maggiore della Carita
Target Recruit Count
260
Registration Number
NCT01148147
Locations
🇮🇹

Giuseppe De Luca, Novara, Italy

Adenosine Cardioplegia; Improved Cardioprotection?

Phase 1
Completed
Conditions
Angina Pectoris
Interventions
Drug: Adenosine
First Posted Date
2010-05-14
Last Posted Date
2011-09-30
Lead Sponsor
University Hospital of North Norway
Target Recruit Count
60
Registration Number
NCT01123525
Locations
🇳🇴

University Hospital of North Norway, Troomsø, Norway

Efficacy and Safety Study of Binodenoson in Assessing Cardiac Ischemia

Phase 3
Completed
Conditions
Coronary Artery Disease
Interventions
Drug: binodenoson
Drug: adenosine
First Posted Date
2009-07-23
Last Posted Date
2012-06-01
Lead Sponsor
Pfizer
Target Recruit Count
419
Registration Number
NCT00944294

Efficacy and Safety Study of Binodenoson in Assessing Cardiac Ischemia

Phase 3
Completed
Conditions
Coronary Artery Disease
Interventions
Drug: binodenoson
Drug: adenosine
First Posted Date
2009-07-23
Last Posted Date
2012-06-01
Lead Sponsor
Pfizer
Target Recruit Count
578
Registration Number
NCT00944970

Endothelial and Metabolic Effects of Glucagon-like Peptide-1 (GLP-1) in Coronary Circulation in Patients With Type 2 Diabetes Mellitus

Not Applicable
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Glucagon like peptide-1
Drug: Adenosine
First Posted Date
2009-06-18
Last Posted Date
2012-09-18
Lead Sponsor
University Hospital, Gentofte, Copenhagen
Target Recruit Count
35
Registration Number
NCT00923962
Locations
🇩🇰

University Hospital Gentofte, Department of Cardiology, Gentofte, Denmark

Myocardial Protection With Adenosine Preconditioning

First Posted Date
2009-04-15
Last Posted Date
2009-04-15
Lead Sponsor
Xijing Hospital
Target Recruit Count
238
Registration Number
NCT00881686
Locations
🇨🇳

Institute of Cardiovascular Surgery, Xijing Hospital, Xi'an, Shannxi, China

Effects of Body Mass Index on the Hyperemic Response to Regadenoson

First Posted Date
2009-03-11
Last Posted Date
2011-05-24
Lead Sponsor
University of Utah
Target Recruit Count
30
Registration Number
NCT00859833
Locations
🇺🇸

University of Utah, Salt Lake City, Utah, United States

Prevention of Liver Damage During Liver Surgery

First Posted Date
2009-02-18
Last Posted Date
2009-02-18
Lead Sponsor
Ludwig-Maximilians - University of Munich
Registration Number
NCT00845689
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy